udonitrectag (REC 0559) / Recordati, MimeTech - LARVOL DELTA

Mimicking Nature, Modulating Vision: Peptidomimetic Neurotrophin Agonists and Emerging Regenerative Strategies in Ocular Disease. (PubMed, Front Biosci (Landmark Ed)) - "This review highlights the development of neurotrophin receptor agonists-including recombinant nerve growth factor (NGF) (cenegermin), peptidomimetics (e.g., REC-0559, tavilermide), and synthetic microneurotrophins (BNN27, ENT-A010)-that target tropomyosin receptor kinases (TrkA/TrkB) and the p75 neurotrophin receptor (p75NTR) pathways to promote neuronal survival, synaptic plasticity, and tissue repair in neurotrophic keratitis, dry eye disease, and retinal degenerations. Parallel advances in peptide-based therapies address vascular and inflammatory pathologies: UPARANT and its derivatives modulate urokinase plasminogen activator receptor (uPAR)/formyl peptide receptor (FPR) signaling to inhibit angiogenesis and inflammation in diabetic retinopathy, whereas sphingosine 1 phosphate (S1P)-S1PR3 pepducins and integrin antagonists (risuteganib, THR-687, OTT166) offer multi-targeted strategies to stabilize the blood-retinal barrier and mitigate neovascularization...Further,..."

Journal • Review • CNS Disorders • Diabetic Retinopathy • Dry Eye Disease • Inflammation • Keratitis • Ocular Inflammation • Ophthalmology • Retinal Disorders • NGFR • NTRK2